Millions of Americans are utilizing medical cannabis and psilocybin to treat specific medical conditions each day. However, scientific and medical research lags in the U.S. lags behind other nations. Dr. Stephen M. Dahmer, Chief Medical Officer at Vireo Health, and Betty Aldworth, Director of Communications and Events at the Multidisciplinary Association for Psychedelic Studies (MAPS) join Perkins Coie senior counsel Andrew Kline to discuss the current dilemma and a path forward. During the podcast, the group discusses the current state of cannabis and psilocybin research, the barriers faced by researchers, and why it is critically important to have people who understand the science involved in policymaking.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.